Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study

---

The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers

---

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...

---

Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.

---

Churchill Pharmaceuticals Expands Commercial Leadership Team

King of Prussia, PA., May 30, 2017 Churchill Pharmaceuticals, LLC (Churchill), a clinical-stage biopharmaceutical company, today announced the expansion of...

---

Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment

King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application...

---

Churchill Pharmaceuticals launches a new updated website with a fresh design

King of Prussia, PA., May 16, 2017 Churchill Pharmaceuticals, a drug development biopharmaceutical company specialized in oral oncology, announced the...

---

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects, Clinical Pharmacokinetics 2017

Click here to view the article.

---